Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells

详细信息    查看全文

• 作者：Feifei Xu ; Fengliang Wang ; Ting Yang ; Yuan Sheng ; Ting Zhong…
• 关键词：Multi ; drug Resistance Acquisition (MDR) ; P ; glycoprotein (P ; gp) ; Drug ; specific ; Doxorubicin (DOX) ; Paclitaxel (PTX)
• 刊名：Cancer Cell International
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：2,797 KB
• 参考文献：1. Altan, N, Chen, Y, Schindler, M, Simon, SM (1998) Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 187: pp. 1583-1598 CrossRef
  2. Faneyte, IF, Kristel, PM, Vijver, MJ (2001) Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93: pp. 114-122 CrossRef
  3. Glavinas, H, Krajcsi, P, Cserepes, J, Sarkadi, B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1: pp. 27-42 CrossRef
  4. Juliano, RL, Ling, V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: pp. 152-162 CrossRef
  5. Gottesman, MM, Pastan, I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: pp. 385-427 CrossRef
  6. Bain, LJ, McLachlan, JB, LeBlanc, GA (1997) Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect 105: pp. 812-818 CrossRef
  7. Guo, B, Villeneuve, DJ, Hembruff, SL, Kirwan, AF, Blais, DE, Bonin, M, Parissenti, AM (2004) Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 85: pp. 31-51 CrossRef
  8. Villeneuve, DJ, Hembruff, SL, Veitch, Z, Cecchetto, M, Dew, WA, Parissenti, AM (2006) cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 96: pp. 17-39 CrossRef
  9. Hartz, AM, Bauer, B, Fricker, G, Miller, DS (2006) Rapid modulation of P-glycoprotein-mediated transport at the blood–brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 69: pp. 462-470 CrossRef
  10. Assef, Y, Rubio, F, Colo, G, Monaco, S, Costas, MA, Kotsias, BA (2009) Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leuk Res 33: pp. 710-716 CrossRef
  11. Kooij G, van Horssen J, de Lange ECM, Reijerkerk A, van der Pol SMA, van het Hof B, Drexhage J, Vennegoor A, Killestein J, Scheffer G, Oerlemans R, Scheper R, van der Valk P, Dijkstra CD, de Vries HE: T lymphocytes impair P-glycoprotein function during neuroinflammation. / J Autoimmun 2010, 34(4):416-25.
  12. Chen, Y, Nie, D (2009) Pregnane X receptor and its potential role in drug resistance in cancer treatment. Recent Pat Anticancer Drug Discov 4: pp. 19-27 CrossRef
  13. Sinz, M, Kim, S, Zhu, Z, Chen, T, Anthony, M, Dickinson, K, Rodrigues, AD (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7: pp. 375-388 CrossRef
  14. Tsan, MF, Gao, B (2004) Endogenous ligands of Toll-like receptors. J Leukoc Biol 76: pp. 514-519 CrossRef
  15. Kawai, T, Akira, S (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13: pp. 460-469 CrossRef
  16. Ying W, Wang S, Shi J, Sun Y:
• 刊物主题：Cancer Research; Cell Biology;
• 出版者：BioMed Central
• ISSN：1475-2867

文摘

Background Several signal transduction pathways have been reported being involved in the acquisition of P-glycoprotein (P-gp) mediated multi-drug resistance (MDR) upon exposure to anti-cancer drugs, whereas there is evidence indicating that the expression and activity of P-gp were not equally or even reversely modulated by different drugs. Methods To further illustrate this drug-specific effect, possible mechanisms that enable breast cancer cells MCF-7 to acquire MDR to either paclitaxel (PTX) or doxorubicin (DOX) were investigated in a time-dependent manner. Results The results suggested that at least two pathways participated in this process. One was the short and transient activation of NF-κB, the second one was the relatively prolonged induction of PXR. Both PXR and NF-κB pathways took part in the PTX drug resistance acquisition, whereas DOX did not exert a significant effect on the PXR-mediated induction of P-gp. Furthermore, the property of NF-κB activation shared by DOX and PTX was not identical. An attempt made in the present study demonstrated that the acquired resistance to DOX was via or partially via NF-κB activation but not its upstream receptor TLR4, while PTX can induce the drug resistance via TLR4-NF-κB pathway. Conclusions To our knowledge, this report is among the first to directly compare the time dependence of NF-κB and PXR pathways. The current study provides useful insight into the distinct ability of DOX and PTX to induce P-gp mediated MDR in breast cancer. Different strategies may be required to circumvent MDR in the presence of different anti-cancer drugs.